QUICK COMPARISON
Foundayo vs Zepbound: Key Differences
The Short Answer
Foundayo and Zepbound are different medications with different active ingredients. Foundayo (orforglipron) is a daily pill; Zepbound (tirzepatide) is a weekly injection. Both are made by Eli Lilly for weight loss, but they work differently and produce different results.
The main trade-off: Zepbound delivers greater weight loss (~20%), while Foundayo offers greater convenience (daily pill, no food restrictions, no refrigeration, lower cost).
| Feature | Foundayo | Zepbound |
|---|---|---|
| Active Ingredient | Orforglipron | Tirzepatide |
| Drug Class | GLP-1 agonist (single) | GIP/GLP-1 agonist (dual) |
| Administration | Daily pill | Weekly injection |
| Food Restrictions | None | None |
| Refrigeration | Not required | Required (2-8°C) |
| Weight Loss | ~12.4% at highest dose[1] | ~20.9% at highest dose[2] |
| LillyDirect Price | $149–$299/month | $299–$449/month† |
| FDA Approval | April 2026 | November 2023 |
For more GLP-1 comparisons, see our Foundayo alternatives guide.
SCIENCE EXPLAINED
How They Work: Different Mechanisms
Both medications help with weight loss by mimicking gut hormones, but they work differently:
Foundayo: GLP-1 Only (Single Mechanism)
Orforglipron activates only GLP-1 receptors, leading to:
- Reduced appetite and increased fullness
- Slower gastric emptying (food stays in stomach longer)
- Improved blood sugar regulation
Unique advantage: Foundayo is a non-peptide "small molecule" — unlike peptide drugs, it doesn't require refrigeration and can be taken any time without food restrictions.
Zepbound: Dual GIP/GLP-1 (Two Mechanisms)
Tirzepatide activates both GIP and GLP-1 receptors, providing:
- All the GLP-1 benefits above, plus...
- GIP activation enhances insulin secretion and fat metabolism
- Combined effect produces greater weight loss than GLP-1 alone
Trade-off: Higher efficacy requires weekly self-injection and refrigerated storage.
Why Zepbound Works Better for Weight Loss
The dual GIP/GLP-1 mechanism is likely why Zepbound produces ~20% weight loss compared to Foundayo's ~12%. For patients prioritizing maximum weight loss, Zepbound is the more effective option. For patients prioritizing convenience, Foundayo offers meaningful weight loss in an easier format.
CLINICAL DATA
Weight Loss Results: What the Trials Show
Both drugs have strong clinical trial evidence, though no head-to-head comparison exists.
| Trial | Drug | Dose | Duration | Weight Loss |
|---|---|---|---|---|
| ATTAIN-1 | Foundayo | 17.2mg* | 72 weeks | 12.4% (~27 lbs)[1] |
| SURMOUNT-1 | Zepbound | 15mg | 72 weeks | 20.9% (~48 lbs)[2] |
*ATTAIN-1 used investigational 36mg capsules; the commercial 17.2mg tablet was shown to be bioequivalent. Results may vary.
Responder Rates
| Weight Loss Achieved | Foundayo (17.2mg)*[1] | Zepbound (15mg)[2] |
|---|---|---|
| ≥5% weight loss | 77% | 91% |
| ≥10% weight loss | 60% | 84% |
| ≥15% weight loss | 40% | 69% |
| ≥20% weight loss | — | 56% |
Cross-Trial Comparison Caveat
These trials had different patient populations. Direct comparison should be made with caution. Both medications produce clinically meaningful weight loss, but Zepbound consistently shows higher efficacy across studies.
WHAT YOU'LL PAY
Cost Comparison: 2026 Pricing
Both medications are available through LillyDirect at similar price points, making them more accessible than many GLP-1s.
| Access Type | Foundayo | Zepbound |
|---|---|---|
| LillyDirect (Self-Pay) | $149–$299/month* | $299–$449/month† |
| Savings Card (With Insurance) | As low as $25/month | As low as $25/month |
| Retail Pharmacy | ~$800-1,000/month | ~$1,000-1,100/month |
*Foundayo: $149 / $149 / $199 / $299 / $299 / $299 by dose (0.8 / 2.5 / 5.5 / 9 / 14.5 / 17.2 mg); 2.5 mg and 5.5 mg prices are temporarily reduced through December 31, 2026; 14.5 mg and 17.2 mg are $349 if a refill is more than 45 days late. †Zepbound: $299 (2.5mg starting), $399 (5mg), $449 (7.5mg–15mg, refill within 45 days).
Foundayo LillyDirect Pricing by Dose
| Dose | Monthly Price | Notes |
|---|---|---|
| 0.8mg (starting) | $149 | Titration dose |
| 2.5mg | $149 | Titration dose (temporarily reduced through December 31, 2026; regular price $199) |
| 5.5mg | $199 | Temporarily reduced through December 31, 2026; regular price $299 |
| 9mg | $299 | Maintenance dose |
| 14.5mg – 17.2mg | $299 (or $349*) | *$349 if a refill is more than 45 days late |
For complete cost details, see our Foundayo cost guide or LillyDirect pricing breakdown.
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
"I found Honest Care online and was very impressed with the letter... the appeal worked!"
"My Appeal was approved the next day. Thank you Honest Care!"
COVERAGE REALITY
Insurance Coverage: What's Covered?
Both Foundayo and Zepbound face insurance barriers for weight loss, but Zepbound has one additional coverage pathway.
| Coverage Type | Foundayo | Zepbound |
|---|---|---|
| Commercial Insurance | Varies — coverage policies forming | Varies — often excluded for weight loss |
| Medicare Part D | Medicare GLP-1 Bridge: $50 per monthly fill (with conditions) | Medicare GLP-1 Bridge (KwikPen only): $50 per monthly fill (with conditions) |
| OSA Indication | Not available | Yes — may improve coverage |
| Appeal Success Rate | 65%+ with proper documentation[3] | |
Key Coverage Differences
- Foundayo — Launched April 2026, coverage policies are still forming. As a new drug, expect prior authorization requirements and potential formulary exclusions initially.
- Zepbound — More established but still faces weight loss exclusions. However, Zepbound's OSA (obstructive sleep apnea) indication may provide an alternative coverage pathway for patients with that condition.
What About Mounjaro?
If you have type 2 diabetes, Mounjaro (same drug as Zepbound — tirzepatide) may be easier to get covered since it's FDA-approved for diabetes, which insurers cover more readily. This is NOT a Foundayo option — Foundayo is a different drug (orforglipron). Talk to your doctor about whether Mounjaro is appropriate for you.
For coverage guidance, see our Foundayo insurance guide. If denied either medication, we can help you appeal — 65%+ of appeals succeed with proper documentation.
DECISION GUIDE
Which Is Right for You?
Neither medication is universally "better" — the right choice depends on your priorities.
| Your Priority | Best Choice | Why |
|---|---|---|
| Maximum weight loss | Zepbound | ~20% vs ~12% weight loss |
| No needles/injections | Foundayo | Daily pill, no self-injection |
| Lowest starting cost | Foundayo | $149/month vs $299/month |
| No refrigeration needed | Foundayo | Travels easily, no cold chain |
| Once-weekly dosing | Zepbound | Less frequent than daily pill |
| Needle anxiety | Foundayo | No injection required |
| Sleep apnea (OSA) | Zepbound | FDA-approved for OSA |
The Maintenance Pathway
Some patients use both medications strategically:
Start with Zepbound
Use the more effective medication to reach your weight loss goal faster.
Reach Your Goal
Once at target weight, discuss transition options with your doctor.
Maintain with Foundayo
Switch to the more convenient oral pill for long-term maintenance.
Transition Considerations
Based on the efficacy difference (~20% vs ~12% weight loss), some weight regain may occur when switching from a higher-efficacy medication to Foundayo for maintenance. Discuss this trade-off with your doctor to determine if maintenance convenience outweighs maximum weight loss.
WHAT YOU NEED TO KNOW
Switching Between Foundayo and Zepbound
Important: Different Medications
Foundayo (orforglipron) and Zepbound (tirzepatide) are different drugs. Switching between them is NOT like switching brands of the same medication — it requires physician guidance on dosing.
How to Switch
Talk to Your Doctor
Discuss why you want to switch (convenience, side effects, cost, maintenance phase). Your doctor will determine if switching is appropriate.
Get a New Prescription
Since these are different medications, you'll need a new prescription. There's no direct dose equivalence between orforglipron and tirzepatide.
Check Insurance Coverage
Verify the new medication is covered. Prior authorization may be required even if you were on another GLP-1.
Common Reasons for Switching
- Zepbound → Foundayo: Needle fatigue, want pill convenience, reached goal weight (maintenance)
- Foundayo → Zepbound: Want greater weight loss, prefer once-weekly dosing, have OSA indication
- Insurance changes: Coverage or formulary changes may make one option more accessible
- Side effects: Some patients tolerate one medication better than the other
COMMON QUESTIONS
Frequently Asked Questions
No. Foundayo (orforglipron) and Zepbound (tirzepatide) are completely different medications. Foundayo is a daily pill that works through GLP-1 only, achieving ~12% weight loss. Zepbound is a weekly injection with dual GIP/GLP-1 action, achieving ~20% weight loss. Both are made by Eli Lilly but contain different active ingredients.
No. Mounjaro contains tirzepatide — the same drug as Zepbound, just with a different FDA approval (for type 2 diabetes). Foundayo contains orforglipron, which is a completely different medication from both Mounjaro and Zepbound.
Zepbound shows greater weight loss (~20.9% at 15mg) compared to Foundayo (~12.4% at highest dose). Zepbound's dual GIP/GLP-1 mechanism likely explains this difference. However, Foundayo offers meaningful weight loss in a more convenient pill format.
Via LillyDirect, both have tiered pricing. Foundayo currently runs $149–$299/month by dose ($349 for the top doses if a refill is late). Zepbound runs $299–$449/month by dose. At starting doses, Foundayo is cheaper ($149 vs $299). With commercial insurance and savings cards, both can cost as little as $25.
Yes, but with physician guidance. Since they're different medications (tirzepatide vs. orforglipron), your doctor will determine appropriate dosing. Common reasons to switch include wanting pill convenience or transitioning to maintenance after reaching weight loss goals.
Choose Foundayo if you prefer a daily pill over injections, have needle anxiety, want no refrigeration requirements, need the lowest starting cost ($149 vs $299), or are in a maintenance phase after achieving weight loss goals. Choose Zepbound if maximum weight loss is your priority.
YOUR PATH FORWARD
What's Next
Learn More About These Medications
Explore complete guides for coverage, costs, and appeals:
References
- Wharton S, Aronne LJ, Stefanski A, et al. "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment." N Engl J Med. 2025;393(18):1796-1806. DOI: 10.1056/NEJMoa2511774 · PMID: 40960239
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038 · PMID: 35658024
- Based on Honest Care internal data from medical necessity appeals. Individual results may vary by plan and documentation quality.
- Eli Lilly and Company. (2026). "FDA Approves Foundayo (orforglipron)." Press Release, April 1, 2026.
- Eli Lilly and Company. (2023). "FDA Approves Zepbound (tirzepatide) for Chronic Weight Management." Press Release, November 8, 2023.
Reviewed by Honest Care GLP-1 SpecialistsLast updated October 6, 2026 · Key facts verified October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.